Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
investor
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2025-03-25
Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients
More
2023-12-19
Novamab has completed a round B financing of more than 100 million yuan
More
2023-11-13
The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
More
2023-09-18
The first and only approved Nanobody drug in China contribute tothe performance growth of three listed companies! What are other potential Nanobody drugs in China?
More
2023-07-04
CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum
More
2023-06-28
LQ036 IND application for COPD accepted by CDE
More
2023-05-25
Novamab presented the latest progress of 3 core assets at the ATS 2023 conference
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
More
总计 51 123456